The client has pseudomembranous colitis (C. diff) and is prescribed metronidazole for treatment. Which statement reflects correct teaching regarding metronidazole therapy?

Introduction: Metronidazole is a nitroimidazole antimicrobial that disrupts DNA synthesis in anaerobic bacteria and protozoa. It is a primary treatment for Clostridioides difficile, but it carries a significant risk for a disulfiram-like reaction if metabolic pathways are interfered with by specific exogenous toxins such as ethanol. A. While some broad-spectrum antibiotics are theorized to interfere with the enterohepatic circulation of estrogen in oral contraceptives, metronidazole does not have a strong clinical association with reduced contraceptive efficacy. Patients are generally not required to use backup barrier methods solely due to the initiation of a metronidazole prescription. B. Metronidazole interferes with the hepatic metabolism of ethanol by inhibiting the enzyme acetaldehyde dehydrogenase. This leads to the accumulation of acetaldehyde, resulting in a severe disulfiram-like reaction characterized by flushing, nausea, vomiting, tachycardia, and abdominal cramps. This restriction must continue for 72 hours after the final dose. C. While oral metronidazole is commonly used for mild to moderate C. diff, it is not the only effective form. Intravenous metronidazole may be utilized in patients with ileus or those who cannot tolerate oral intake, often in combination with vancomycin administered via other routes to ensure the pathogen is reached. D. Photosensitivity is a common side effect of other antimicrobial classes, such as tetracyclines and fluoroquinolones, but it is not a typical adverse effect associated with metronidazole. While general sun safety is always encouraged, there is no specific pharmacological requirement for patients on metronidazole to avoid sunlight to prevent cutaneous reactions.